Abstract

Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are pathogenically related nonmalignant bone marrow failure disorders linked to T-cell–mediated autoimmunity; they are associated with an increased risk of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Approximately 15% to 20% of AA patients and 2% to 6% of PNH patients go on to develop secondary MDS/AML by 10 years of follow-up. Factors determining an individual patient’s risk of malignant transformation remain poorly defined. Recent studies identified nearly ubiquitous clonal hematopoiesis (CH) in AA patients. Similarly, CH with additional, non-PIGA, somatic alterations occurs in the majority of patients with PNH. Factors associated with progression to secondary MDS/AML include longer duration of disease, increased telomere attrition, presence of adverse prognostic mutations, and multiple mutations, particularly when occurring early in the disease course and at a high allelic burden. Here, we will review the prevalence and characteristics of somatic alterations in AA and PNH and will explore their prognostic significance and mechanisms of clonal selection. We will then discuss the available data on post-AA and post-PNH progression to secondary MDS/AML and provide practical guidance for approaching patients with PNH and AA who have CH.

REFERENCES

1.
Camitta
BM
,
Storb
R
,
Thomas
ED
.
Aplastic anemia (second of two parts): pathogenesis, diagnosis, treatment, and prognosis
.
N Engl J Med
.
1982
;
306
(
12
):
712
-
718
.
2.
Young
NS
.
Aplastic anemia
.
N Engl J Med
.
2018
;
379
(
17
):
1643
-
1656
.
3.
Hill
A
,
DeZern
AE
,
Kinoshita
T
,
Brodsky
RA
.
Paroxysmal nocturnal haemoglobinuria
.
Nat Rev Dis Primers
.
2017
;
3
:
17028
.
4.
DeZern
AE
,
Brodsky
RA
.
Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia
.
Hematol Oncol Clin North Am
.
2015
;
29
(
3
):
479
-
494
.
5.
Rotoli
B
,
Luzzatto
L
.
Paroxysmal nocturnal haemoglobinuria
.
Baillieres Clin Haematol
.
1989
;
2
(
1
):
113
-
138
.
6.
Rotoli
B
,
Luzzatto
L
.
Paroxysmal nocturnal hemoglobinuria
.
Semin Hematol
.
1989
;
26
(
3
):
201
-
207
.
7.
Luzzatto
L
,
Bessler
M
,
Rotoli
B
.
Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?
Cell
.
1997
;
88
(
1
):
1
-
4
.
8.
Luzzatto
L
,
Risitano
AM
.
Advances in understanding the pathogenesis of acquired aplastic anaemia
.
Br J Haematol
.
2018
;
182
(
6
):
758
-
776
.
9.
Dameshek
W
.
Riddle: what do aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH) and “hypoplastic” leukemia have in common?
Blood
.
1967
;
30
(
2
):
251
-
254
.
10.
Socié
G
,
Henry-Amar
M
,
Bacigalupo
A
, et al;
European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party
.
Malignant tumors occurring after treatment of aplastic anemia
.
N Engl J Med
.
1993
;
329
(
16
):
1152
-
1157
.
11.
Socié
G
.
Could aplastic anaemia be considered a pre-pre-leukaemic disorder?
Eur J Haematol Suppl
.
1996
;
60
:
60
-
63
.
12.
de Planque
MM
,
Bacigalupo
A
,
Würsch
A
, et al;
Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT)
.
Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin
.
Br J Haematol
.
1989
;
73
(
1
):
121
-
126
.
13.
Tichelli
A
,
Gratwohl
A
,
Würsch
A
,
Nissen
C
,
Speck
B
.
Late haematological complications in severe aplastic anaemia
.
Br J Haematol
.
1988
;
69
(
3
):
413
-
418
.
14.
Tichelli
A
,
Gratwohl
A
,
Nissen
C
,
Speck
B
.
Late clonal complications in severe aplastic anemia
.
Leuk Lymphoma
.
1994
;
12
(
3-4
):
167
-
175
.
15.
Tichelli
A
,
Schrezenmeier
H
,
Socié
G
, et al
.
A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation
.
Blood
.
2011
;
117
(
17
):
4434
-
4441
.
16.
Rosenfeld
S
,
Follmann
D
,
Nunez
O
,
Young
NS
.
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome
.
JAMA
.
2003
;
289
(
9
):
1130
-
1135
.
17.
Frickhofen
N
,
Heimpel
H
,
Kaltwasser
JP
,
Schrezenmeier
H
;
German Aplastic Anemia Study Group
.
Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia
.
Blood
.
2003
;
101
(
4
):
1236
-
1242
.
18.
Socié
G
,
Rosenfeld
S
,
Frickhofen
N
,
Gluckman
E
,
Tichelli
A
.
Late clonal diseases of treated aplastic anemia
.
Semin Hematol
.
2000
;
37
(
1
):
91
-
101
.
19.
Nishimura
J
,
Kanakura
Y
,
Ware
RE
, et al
.
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan
.
Medicine (Baltimore)
.
2004
;
83
(
3
):
193
-
207
.
20.
de Latour
RP
,
Mary
JY
,
Salanoubat
C
, et al;
French Association of Young Hematologists
.
Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories
.
Blood
.
2008
;
112
(
8
):
3099
-
3106
.
21.
Cooper
JN
,
Young
NS
.
Clonality in context: hematopoietic clones in their marrow environment
.
Blood
.
2017
;
130
(
22
):
2363
-
2372
.
22.
Young
AL
,
Challen
GA
,
Birmann
BM
,
Druley
TE
.
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
.
Nat Commun
.
2016
;
7
:
12484
.
23.
Zink
F
,
Stacey
SN
,
Norddahl
GL
, et al
.
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
.
Blood
.
2017
;
130
(
6
):
742
-
752
.
24.
Jaiswal
S
,
Fontanillas
P
,
Flannick
J
, et al
.
Age-related clonal hematopoiesis associated with adverse outcomes
.
N Engl J Med
.
2014
;
371
(
26
):
2488
-
2498
.
25.
Genovese
G
,
Kähler
AK
,
Handsaker
RE
, et al
.
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
.
N Engl J Med
.
2014
;
371
(
26
):
2477
-
2487
.
26.
Holstege
H
,
Pfeiffer
W
,
Sie
D
, et al
.
Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis
.
Genome Res
.
2014
;
24
(
5
):
733
-
742
.
27.
Challen
GA
,
Sun
D
,
Jeong
M
, et al
.
Dnmt3a is essential for hematopoietic stem cell differentiation
.
Nat Genet
.
2011
;
44
(
1
):
23
-
31
.
28.
Moran-Crusio
K
,
Reavie
L
,
Shih
A
, et al
.
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
.
Cancer Cell
.
2011
;
20
(
1
):
11
-
24
.
29.
Abelson
S
,
Collord
G
,
Ng
SWK
, et al
.
Prediction of acute myeloid leukaemia risk in healthy individuals
.
Nature
.
2018
;
559
(
7714
):
400
-
404
.
30.
Malcovati
L
,
Gallì
A
,
Travaglino
E
, et al
.
Clinical significance of somatic mutation in unexplained blood cytopenia
.
Blood
.
2017
;
129
(
25
):
3371
-
3378
.
31.
Nagase
R
,
Inoue
D
,
Pastore
A
, et al
.
Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation
.
J Exp Med
.
2018
;
215
(
6
):
1729
-
1747
.
32.
Kelly
MJ
,
So
J
,
Rogers
AJ
, et al
.
Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis
.
Nat Commun
.
2019
;
10
(
1
):
1347
.
33.
Long
Z
,
Li
H
,
Du
Y
,
Wang
Z
,
Han
B
.
Gene mutation profile in patients with acquired pure red cell aplasia [abstract]
.
Blood
.
2018
;
132
(
suppl 1
). Abstract
2592
.
34.
Ibrahimi
S
,
George
J
,
Gaffney
PM
,
Vesely
SK
,
Asch
AS
.
Role of somatic mutations and clonal thrombopoiesis in immune thrombocytopenia [abstract]
.
Blood
.
2018
;
132
(
suppl 1
). Abstract
130
.
35.
Lane
AA
,
Odejide
O
,
Kopp
N
, et al
.
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia
.
Leukemia
.
2013
;
27
(
4
):
968
-
971
.
36.
Shen
W
,
Clemente
MJ
,
Hosono
N
, et al
.
Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria
.
J Clin Invest
.
2014
;
124
(
10
):
4529
-
4538
.
37.
Yoshizato
T
,
Dumitriu
B
,
Hosokawa
K
, et al
.
Somatic mutations and clonal hematopoiesis in aplastic anemia
.
N Engl J Med
.
2015
;
373
(
1
):
35
-
47
.
38.
Babushok
DV
,
Perdigones
N
,
Perin
JC
, et al
.
Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia
.
Cancer Genet
.
2015
;
208
(
4
):
115
-
128
.
39.
Welch
JS
,
Ley
TJ
,
Link
DC
, et al
.
The origin and evolution of mutations in acute myeloid leukemia
.
Cell
.
2012
;
150
(
2
):
264
-
278
.
40.
Scheinberg
P
,
Marte
M
,
Nunez
O
,
Young
NS
.
Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine
.
Haematologica
.
2010
;
95
(
7
):
1075
-
1080
.
41.
Luzzatto
L
,
Notaro
R
.
The “escape” model: a versatile mechanism for clonal expansion
.
Br J Haematol
.
2019
;
184
(
3
):
465
-
466
.
42.
Dunn
DE
,
Tanawattanacharoen
P
,
Boccuni
P
, et al
.
Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes
.
Ann Intern Med
.
1999
;
131
(
6
):
401
-
408
.
43.
Raza
A
,
Ravandi
F
,
Rastogi
A
, et al
.
A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure
.
Cytometry B Clin Cytom
.
2014
;
86
(
3
):
175
-
182
.
44.
Kinoshita
T
,
Inoue
N
.
Relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria
.
Int J Hematol
.
2002
;
75
(
2
):
117
-
122
.
45.
Gutwein
O
,
Englander
Y
,
Herzog-Tzarfati
K
, et al
.
Prevalence of paroxysmal nocturnal hemoglobinuria clones in myeloproliferative neoplasm patients: a cross-sectional study
.
Clin Lymphoma Myeloma Leuk
.
2019
;
19
(
12
):
812
-
814
.
46.
Keller
P
,
Tremml
G
,
Rosti
V
,
Bessler
M
.
X inactivation and somatic cell selection rescue female mice carrying a Piga-null mutation
.
Proc Natl Acad Sci USA
.
1999
;
96
(
13
):
7479
-
7483
.
47.
Shin
TH
,
Baek
EJ
,
Corat
MAF
, et al
.
CRISPR/Cas9 PIG-A gene editing in nonhuman primate model demonstrates no intrinsic clonal expansion of PNH HSPCs
.
Blood
.
2019
;
133
(
23
):
2542
-
2545
.
48.
Maciejewski
JP
,
Sloand
EM
,
Sato
T
,
Anderson
S
,
Young
NS
.
Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone
.
Blood
.
1997
;
89
(
4
):
1173
-
1181
.
49.
Murakami
Y
,
Inoue
N
,
Shichishima
T
, et al
.
Deregulated expression of HMGA2 is implicated in clonal expansion of PIGA deficient cells in paroxysmal nocturnal haemoglobinuria
.
Br J Haematol
.
2012
;
156
(
3
):
383
-
387
.
50.
Hanaoka
N
,
Murakami
Y
,
Nagata
M
, et al
.
Occupancy of whole blood cells by a single PIGA-mutant clone with HMGA2 amplification in a paroxysmal nocturnal haemoglobinuria patient having blood cells with NKG2D ligands
.
Br J Haematol
.
2013
;
160
(
1
):
114
-
116
.
51.
Negoro
E
,
Nagata
Y
,
Clemente
MJ
, et al
.
Origins of myelodysplastic syndromes after aplastic anemia
.
Blood
.
2017
;
130
(
17
):
1953
-
1957
.
52.
Purow
DB
,
Howard
TA
,
Marcus
SJ
,
Rosse
WF
,
Ware
RE
.
Genetic instability and the etiology of somatic PIG-A mutations in paroxysmal nocturnal hemoglobinuria
.
Blood Cells Mol Dis
.
1999
;
25
(
2
):
81
-
91
.
53.
Hattori
H
,
Machii
T
,
Ueda
E
,
Shibano
M
,
Kageyama
T
,
Kitani
T
.
Increased frequency of somatic mutations at glycophorin A loci in patients with aplastic anaemia, myelodysplastic syndrome and paroxysmal nocturnal haemoglobinuria
.
Br J Haematol
.
1997
;
98
(
2
):
384
-
391
.
54.
Horikawa
K
,
Kawaguchi
T
,
Ishihara
S
, et al
.
Frequent detection of T cells with mutations of the hypoxanthine-guanine phosphoribosyl transferase gene in patients with paroxysmal nocturnal hemoglobinuria
.
Blood
.
2002
;
99
(
1
):
24
-
29
.
55.
Araten
DJ
,
Luzzatto
L
.
The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH)
.
Blood
.
2006
;
108
(
2
):
734
-
736
.
56.
Hillmen
P
,
Lewis
SM
,
Bessler
M
,
Luzzatto
L
,
Dacie
JV
.
Natural history of paroxysmal nocturnal hemoglobinuria
.
N Engl J Med
.
1995
;
333
(
19
):
1253
-
1258
.
57.
Nagakura
S
,
Ishihara
S
,
Dunn
DE
, et al
.
Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro
.
Blood
.
2002
;
100
(
3
):
1031
-
1037
.
58.
Hanaoka
N
,
Kawaguchi
T
,
Horikawa
K
,
Nagakura
S
,
Mitsuya
H
,
Nakakuma
H
.
Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP
.
Blood
.
2006
;
107
(
3
):
1184
-
1191
.
59.
Gargiulo
L
,
Papaioannou
M
,
Sica
M
, et al
.
Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria
.
Blood
.
2013
;
121
(
14
):
2753
-
2761
.
60.
Kunyaboon
R
,
Wanachiwanawin
W
,
U-Pratya
Y
,
Thedsawad
A
,
Taka
O
.
Mechanism of paroxysmal nocturnal hemoglobinuria clonal dominance: possible roles of different apoptosis and CD8+ lymphocytes in the selection of paroxysmal nocturnal hemoglobinuria clones
.
Hematol Oncol Stem Cell Ther
.
2012
;
5
(
3
):
138
-
145
.
61.
Maciejewski
JP
,
Follmann
D
,
Nakamura
R
, et al
.
Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome
.
Blood
.
2001
;
98
(
13
):
3513
-
3519
.
62.
Lombardi
ML
,
Terrazzano
G
,
Cosentini
E
, et al
.
Paroxysmal nocturnal hemoglobinuria: significant association with specific HLA-A, -B, -C, and -DR alleles in an Italian population
.
Hum Immunol
.
2008
;
69
(
3
):
202
-
206
.
63.
Höchsmann
B
,
Murakami
Y
,
Osato
M
, et al
.
Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation
.
J Clin Invest
.
2019
;
129
(
12
):
5123
-
5136
.
64.
Krawitz
PM
,
Höchsmann
B
,
Murakami
Y
, et al
.
A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT
.
Blood
.
2013
;
122
(
7
):
1312
-
1315
.
65.
Babushok
DV
,
Duke
JL
,
Xie
HM
, et al
.
Somatic HLA mutations expose the role of class i-mediated autoimmunity in aplastic anemia and its clonal complications
.
Blood Adv
.
2017
;
1
(
22
):
1900
-
1910
.
66.
Zaimoku
Y
,
Takamatsu
H
,
Hosomichi
K
, et al
.
Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia [published correction appears in Blood. 2017;130(8):1072]
.
Blood
.
2017
;
129
(
21
):
2908
-
2916
.
67.
Katagiri
T
,
Sato-Otsubo
A
,
Kashiwase
K
, et al;
Japan Marrow Donor Program
.
Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia
.
Blood
.
2011
;
118
(
25
):
6601
-
6609
.
68.
Betensky
M
,
Babushok
D
,
Roth
JJ
, et al
.
Clonal evolution and clinical significance of copy number neutral loss of heterozygosity of chromosome arm 6p in acquired aplastic anemia
.
Cancer Genet
.
2016
;
209
(
1-2
):
1
-
10
.
69.
Mohamedali
AM
,
Gäken
J
,
Ahmed
M
, et al
.
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)
.
Leukemia
.
2015
;
29
(
9
):
1928
-
1938
.
70.
Score
J
,
Chase
A
,
Forsberg
LA
, et al
.
Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals
.
Leukemia
.
2015
;
29
(
7
):
1600
-
1602
.
71.
Ueda
Y
,
Nishimura
J
,
Murakami
Y
, et al
.
Paroxysmal nocturnal hemoglobinuria with copy number-neutral 6pLOH in GPI (+) but not in GPI (-) granulocytes
.
Eur J Haematol
.
2014
;
92
(
5
):
450
-
453
.
72.
Yoroidaka
T
,
Hosokawa
K
,
Imi
T
,
Katagiri
T
,
Azuma
F
,
Nakao
S
.
Bystander proliferation of Piga-mutated hematopoietic progenitor cells in acquired aplastic anemia patients possessing HLA class I allele-lacking leukocytes [abstract]
.
Blood
.
2018
;
132
(
suppl 1
). Abstract
1308
.
73.
Kulasekararaj
AG
,
Jiang
J
,
Smith
AE
, et al
.
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome
.
Blood
.
2014
;
124
(
17
):
2698
-
2704
.
74.
Babushok
DV
.
A brief, but comprehensive, guide to clonal evolution in aplastic anemia
.
Hematology Am Soc Hematol Educ Program
.
2018
;
2018
:
457
-
466
.
75.
Babushok
DV
,
Olson
TS
,
Bessler
M
.
Somatic mutations and clonal hematopoiesis in aplastic anemia
.
N Engl J Med
.
2015
;
373
(
17
):
1673
-
1676
.
76.
Young
NS
,
Ogawa
S
.
Somatic mutations and clonal hematopoiesis in aplastic anemia
.
N Engl J Med
.
2015
;
373
(
17
):
1675
-
1676
.
77.
Rogers
ZR
,
Nakano
TA
,
Olson
TS
, et al
.
Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
.
Haematologica
.
2019
;
104
(
10
):
1974
-
1983
.
78.
Stanley
N
,
Olson
TS
,
Babushok
DV
.
Recent advances in understanding clonal haematopoiesis in aplastic anaemia
.
Br J Haematol
.
2017
;
177
(
4
):
509
-
525
.
79.
Arber
DA
,
Orazi
A
,
Hasserjian
R
, et al
.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood. 2016;128(3):462-463]
.
Blood
.
2016
;
127
(
20
):
2391
-
2405
.
80.
Hosokawa
K
,
Katagiri
T
,
Sugimori
N
, et al
.
Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO “MDS-U” designation
.
Haematologica
.
2012
;
97
(
12
):
1845
-
1849
.
81.
Holbro
A
,
Jotterand
M
,
Passweg
JR
,
Buser
A
,
Tichelli
A
,
Rovó
A
.
Comment to “Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO ‘MDS-U’ designation” Haematologica. 2012;97(12):1845-9
.
Haematologica
.
2013
;
98
(
4
):
e46
-
e47
.
82.
Ishiyama
K
,
Karasawa
M
,
Miyawaki
S
, et al
.
Aplastic anaemia with 13q-: a benign subset of bone marrow failure responsive to immunosuppressive therapy
.
Br J Haematol
.
2002
;
117
(
3
):
747
-
750
.
83.
Hosokawa
K
,
Sugimori
N
,
Katagiri
T
, et al
.
Increased glycosylphosphatidylinositol-anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8
.
Eur J Haematol
.
2015
;
95
(
3
):
230
-
238
.
84.
Maciejewski
JP
,
Risitano
A
,
Sloand
EM
,
Nunez
O
,
Young
NS
.
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia
.
Blood
.
2002
;
99
(
9
):
3129
-
3135
.
85.
Dumitriu
B
,
Feng
X
,
Townsley
DM
, et al
.
Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia
.
Blood
.
2015
;
125
(
4
):
706
-
709
.
86.
Araten
DJ
,
Swirsky
D
,
Karadimitris
A
, et al
.
Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria
.
Br J Haematol
.
2001
;
115
(
2
):
360
-
368
.
87.
Ge
M
,
Shi
J
,
Li
X
, et al
.
Clinical features and survival of Asian pediatric patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China
.
Acta Haematol
.
2015
;
134
(
1
):
1
-
6
.
88.
Kim
H
,
Hur
M
,
Moon
HW
,
Park
CM
,
Yun
YM
,
Kim
SY
.
Paroxysmal nocturnal hemoglobinuria with deletion of chromosome 13q (q12q14): a case report and review of the literature
.
Ann Clin Lab Sci
.
2012
;
42
(
3
):
313
-
317
.
89.
Sloand
EM
,
Fuhrer
M
,
Keyvanfar
K
, et al
.
Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive
.
Br J Haematol
.
2003
;
123
(
1
):
173
-
176
.
90.
Inoue
N
,
Izui-Sarumaru
T
,
Murakami
Y
, et al
.
Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH)
.
Blood
.
2006
;
108
(
13
):
4232
-
4236
.
91.
Dacie
JV
,
Lewis
SM
.
Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease
.
Ser Haematol
.
1972
;
5
(
3
):
3
-
23
.
92.
Charache
S
.
Prolonged survival in paroxysmal nocturnal hemoglobinuria
.
Blood
.
1969
;
33
(
6
):
877
-
883
.
93.
Korkama
ES
,
Armstrong
AE
,
Jarva
H
,
Meri
S
.
Spontaneous remission in paroxysmal nocturnal hemoglobinuria-return to health or transition into malignancy?
Front Immunol
.
2018
;
9
:
1749
.
94.
Babushok
DV
,
Stanley
N
,
Xie
HM
, et al
.
Clonal replacement underlies spontaneous remission in paroxysmal nocturnal haemoglobinuria
.
Br J Haematol
.
2017
;
176
(
3
):
487
-
490
.
95.
Socie
G
,
Mary
JY
,
Schrezenmeier
H
, et al
.
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)
.
Blood
.
2007
;
109
(
7
):
2794
-
2796
.
96.
Tichelli
A
,
Gratwohl
A
,
Würsch
A
,
Nissen
C
,
Speck
B
.
Secondary leukemia after severe aplastic anemia
.
Blut
.
1988
;
56
(
2
):
79
-
81
.
97.
Führer
M
,
Burdach
S
,
Ebell
W
, et al;
German/Austrian Pediatric Aplastic Anemia Working Group
.
Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience
.
Klin Padiatr
.
1998
;
210
(
4
):
173
-
179
.
98.
Huang
J
,
Ge
M
,
Lu
S
, et al
.
Mutations of ASXL1 and TET2 in aplastic anemia
.
Haematologica
.
2015
;
100
(
5
):
e172
-
e175
.
99.
Li
Y
,
Li
X
,
Ge
M
, et al
.
Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience
.
Ann Hematol
.
2011
;
90
(
5
):
529
-
537
.
100.
Kojima
S
,
Ohara
A
,
Tsuchida
M
, et al;
Japan Childhood Aplastic Anemia Study Group
.
Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children
.
Blood
.
2002
;
100
(
3
):
786
-
790
.
101.
Ohara
A
,
Kojima
S
,
Hamajima
N
, et al
.
Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia
.
Blood
.
1997
;
90
(
3
):
1009
-
1013
.
102.
Frickhofen
N
,
Kaltwasser
JP
,
Schrezenmeier
H
, et al;
The German Aplastic Anemia Study Group
.
Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine
.
N Engl J Med
.
1991
;
324
(
19
):
1297
-
1304
.
103.
Paquette
RL
,
Tebyani
N
,
Frane
M
, et al
.
Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation
.
Blood
.
1995
;
85
(
1
):
283
-
290
.
104.
Locasciulli
A
,
Arcese
W
,
Locatelli
F
,
Di Bona
E
,
Bacigalupo
A
;
Italian Aplastic Anaemia Study Group
.
Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy
.
Lancet
.
2001
;
357
(
9249
):
43
-
44
.
105.
Townsley
DM
,
Scheinberg
P
,
Winkler
T
, et al
.
Eltrombopag added to standard immunosuppression for aplastic anemia
.
N Engl J Med
.
2017
;
376
(
16
):
1540
-
1550
.
106.
Doney
K
,
Leisenring
W
,
Storb
R
,
Appelbaum
FR
;
Seattle Bone Marrow Transplant Team
.
Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy
.
Ann Intern Med
.
1997
;
126
(
2
):
107
-
115
.
107.
Bacigalupo
A
,
Bruno
B
,
Saracco
P
, et al;
European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO)
.
Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients
.
Blood
.
2000
;
95
(
6
):
1931
-
1934
.
108.
Bat
T
,
Abdelhamid
ON
,
Balasubramanian
SK
, et al
.
The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy
.
Br J Haematol
.
2018
;
182
(
5
):
730
-
733
.
109.
Mikhailova
N
,
Sessarego
M
,
Fugazza
G
, et al
.
Cytogenetic abnormalities in patients with severe aplastic anemia
.
Haematologica
.
1996
;
81
(
5
):
418
-
422
.
110.
Geary
CG
,
Harrison
CJ
,
Philpott
NJ
,
Hows
JM
,
Gordon-Smith
EC
,
Marsh
JC
.
Abnormal cytogenetic clones in patients with aplastic anaemia: response to immunosuppressive therapy
.
Br J Haematol
.
1999
;
104
(
2
):
271
-
274
.
111.
Gupta
V
,
Brooker
C
,
Tooze
JA
, et al
.
Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults
.
Br J Haematol
.
2006
;
134
(
1
):
95
-
99
.
112.
Piaggio
G
,
Podestà
M
,
Pitto
A
, et al
.
Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapy
.
Br J Haematol
.
1999
;
107
(
3
):
505
-
511
.
113.
Ohga
S
,
Ohara
A
,
Hibi
S
, et al;
Aplastic Anaemia Committee of the Japanese Society of Paediatric Haematology
.
Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis
.
Br J Haematol
.
2002
;
118
(
1
):
313
-
319
.
114.
Park
HS
,
Park
SN
,
Im
K
, et al
.
Telomere length and somatic mutations in correlation with response to immunosuppressive treatment in aplastic anaemia
.
Br J Haematol
.
2017
;
178
(
4
):
603
-
615
.
115.
Herbig
U
,
Jobling
WA
,
Chen
BP
,
Chen
DJ
,
Sedivy
JM
.
Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a)
.
Mol Cell
.
2004
;
14
(
4
):
501
-
513
.
116.
Wang
C
,
Zhang
T
,
Wang
Y
, et al
.
The shortening telomere length of T lymphocytes maybe associated with hyper-function in servere aplastic anemia
.
Mol Med Rep
.
2018
;
17
(
1
):
1015
-
1021
.
117.
Scheinberg
P
,
Cooper
JN
,
Sloand
EM
,
Wu
CO
,
Calado
RT
,
Young
NS
.
Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia
.
JAMA
.
2010
;
304
(
12
):
1358
-
1364
.
118.
Niewisch
MR
,
Savage
SA
.
An update on the biology and management of dyskeratosis congenita and related telomere biology disorders
.
Expert Rev Hematol
.
2019
;
12
(
12
):
1037
-
1052
.
119.
Fogarty
PF
,
Yamaguchi
H
,
Wiestner
A
, et al
.
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA
.
Lancet
.
2003
;
362
(
9396
):
1628
-
1630
.
120.
Xie
M
,
Lu
C
,
Wang
J
, et al
.
Age-related mutations associated with clonal hematopoietic expansion and malignancies
.
Nat Med
.
2014
;
20
(
12
):
1472
-
1478
.
121.
Jaiswal
S
,
Natarajan
P
,
Silver
AJ
, et al
.
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
.
N Engl J Med
.
2017
;
377
(
2
):
111
-
121
.
122.
Socié
G
,
Mary
JY
,
de Gramont
A
, et al;
French Society of Haematology
.
Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors
.
Lancet
.
1996
;
348
(
9027
):
573
-
577
.
123.
Ware
RE
,
Hall
SE
,
Rosse
WF
.
Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence
.
N Engl J Med
.
1991
;
325
(
14
):
991
-
996
.
124.
Harris
JW
,
Koscick
R
,
Lazarus
HM
,
Eshleman
JR
,
Medof
ME
.
Leukemia arising out of paroxysmal nocturnal hemoglobinuria
.
Leuk Lymphoma
.
1999
;
32
(
5-6
):
401
-
426
.
125.
Ghosh
K
.
Morphological spectrum of paroxysmal nocturnal hemoglobinuria (PNH)
.
Indian J Hematol Blood Transfus
.
2015
;
31
(
2
):
314
-
316
.
126.
Katahira
J
,
Aoyama
M
,
Oshimi
K
,
Mizoguchi
H
,
Okada
M
.
Paroxysmal nocturnal hemoglobinuria terminating in TdT-positive acute leukemia
.
Am J Hematol
.
1983
;
14
(
1
):
79
-
87
.
127.
Isoda
A
,
Ogawa
Y
,
Matsumoto
M
,
Sawamura
M
.
Coexistence of paroxysmal nocturnal hemoglobinuria (PNH) and acute lymphoblastic leukemia (ALL): is PNH a prodrome of ALL?
Leuk Res
.
2009
;
33
(
3
):
e3
-
e5
.
128.
Chen
Y
,
Tao
S
,
Deng
Y
,
Song
L
,
Yu
L
.
Chronic myeloid leukemia transformation in a patient with paroxysmal nocturnal hemoglobinuria: a rare case report with literature review
.
Int J Clin Exp Med
.
2015
;
8
(
5
):
8226
-
8229
.
129.
Stafford
HA
,
Nagarajan
S
,
Weinberg
JB
,
Medof
ME
.
PIG-A, DAF and proto-oncogene expression in paroxysmal nocturnal haemoglobinuria-associated acute myelogenous leukaemia blasts
.
Br J Haematol
.
1995
;
89
(
1
):
72
-
78
.
130.
Devine
DV
,
Gluck
WL
,
Rosse
WF
,
Weinberg
JB
.
Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone
.
J Clin Invest
.
1987
;
79
(
1
):
314
-
317
.
131.
Tanaka
H
,
Imamura
N
,
Oguma
N
, et al
.
Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome
.
Int J Hematol
.
2001
;
73
(
2
):
206
-
212
.
132.
Shichishima
T
,
Terasawa
T
,
Hashimoto
C
, et al
.
Discordant and heterogeneous expression of GPI-anchored membrane proteins on leukemic cells in a patient with paroxysmal nocturnal hemoglobinuria
.
Blood
.
1993
;
81
(
7
):
1855
-
1862
.
133.
Füreder
W
,
Sperr
WR
,
Gleixner
K
, et al
.
Major response of PNH to an AML chemotherapy protocol
.
Ann Hematol
.
2018
;
97
(
8
):
1487
-
1488
.
134.
Longo
L
,
Bessler
M
,
Beris
P
,
Swirsky
D
,
Luzzatto
L
.
Myelodysplasia in a patient with pre-existing paroxysmal nocturnal haemoglobinuria: a clonal disease originating from within a clonal disease
.
Br J Haematol
.
1994
;
87
(
2
):
401
-
403
.
135.
Cornélis
F
,
Montfort
L
,
Osselaer
JC
, et al
.
Acute leukaemia in paroxysmal nocturnal haemoglobinuria. Case report and review of the literature
.
Hematol Cell Ther
.
1996
;
38
(
3
):
285
-
288
.
136.
Hirsch
VJ
,
Neubach
PA
,
Parker
DM
,
Reese
MH
,
Stone
MJ
.
Paroxysmal nocturnal hemoglobinuria. Termination in acute myelomonocytic leukemia and reappearance after leukemic remission
.
Arch Intern Med
.
1981
;
141
(
4
):
525
-
527
.
137.
Kawano
F
,
Chosa
M
,
Matsuoka
M
,
Oyamada
N
,
Takatsuki
K
.
Paroxysmal nocturnal hemoglobinuria: termination in acute monocytic leukemia and reappearance after chemotherapy with N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) and vincristine
.
Jpn J Clin Oncol
.
1987
;
17
(
2
):
123
-
128
.
138.
Tichelli
A
,
Peffault de Latour
R
,
Passweg
J
, et al
.
Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globuline, cyclosporine, with or without G-CSF: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation
.
Haematologica
.
2020
;
105
(
5
):
1223
-
1231
.
139.
Young
NS
.
G-CSF and monosomy 7 in marrow failure patients
.
Blood
.
2002
;
100
(
3
):
741
.
140.
Alter
BP
,
Rosenberg
PS
.
Granulocyte colony-stimulating factor and severe aplastic anemia
.
Blood
.
2007
;
109
(
10
):
4589
-
4590
.
141.
Olnes
MJ
,
Scheinberg
P
,
Calvo
KR
, et al
.
Eltrombopag and improved hematopoiesis in refractory aplastic anemia
.
N Engl J Med
.
2012
;
367
(
1
):
11
-
19
.
142.
Desmond
R
,
Townsley
DM
,
Dumitriu
B
, et al
.
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
.
Blood
.
2014
;
123
(
12
):
1818
-
1825
.
143.
Winkler
T
,
Fan
X
,
Cooper
J
, et al
.
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag
.
Blood
.
2019
;
133
(
24
):
2575
-
2585
.
144.
Guenther
KL
,
Cheruku
PS
,
Cash
A
, et al
.
Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells
.
Exp Hematol
.
2019
;
73
:
1
-
6.e6
.
145.
ClinicalTrials.gov
.
NCT02099747. hATG+CsA vs hATG+CsA+Eltrombopag for SAA (RACE)
. https://clinicaltrials.gov/ct2/show/NCT02099747
. Accessed September 2019
.
146.
Kelly
RJ
,
Hill
A
,
Arnold
LM
, et al
.
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
.
Blood
.
2011
;
117
(
25
):
6786
-
6792
.
147.
Hillmen
P
,
Muus
P
,
Röth
A
, et al
.
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
.
Br J Haematol
.
2013
;
162
(
1
):
62
-
73
.
148.
Loschi
M
,
Porcher
R
,
Barraco
F
, et al
.
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study
.
Am J Hematol
.
2016
;
91
(
4
):
366
-
370
.
149.
Hillmen
P
,
Young
NS
,
Schubert
J
, et al
.
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
.
N Engl J Med
.
2006
;
355
(
12
):
1233
-
1243
.
150.
Lindsley
RC
,
Mar
BG
,
Mazzola
E
, et al
.
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
.
Blood
.
2015
;
125
(
9
):
1367
-
1376
.
You do not currently have access to this content.

Sign in via your Institution

Sign In